OC
FTXH icon

Oppenheimer & Co’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Oppenheimer & Co’s Portfolio FTXH Stock Details FTXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36M Buy
114,183
+73,630
+182% +$2.56M 0.05% 401
2026
Q1 		$1.39M Buy
+40,553
New +$1.39M 0.02% 729

Other funds holding FTXH

LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
MIM
Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
NP
Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Oppenheimer & Co's FTXH Position: Q2 2026 in Review

Oppenheimer & Co increased its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 182% in Q2 2026, buying an estimated $2.56M and bringing the position to 114,183 shares worth $4.36M. The position accounts for 0.05% of the portfolio, ranked #401.

Oppenheimer & Co first reported a position in FTXH in Q1 2026 and has held it in 2 quarters since. 31 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

  • Oppenheimer & Co held 114,183 shares of First Trust Nasdaq Pharmaceuticals ETF worth $4.36M as of Q2 2026.
  • Oppenheimer & Co bought 73,630 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $2.56M.
  • First Trust Nasdaq Pharmaceuticals ETF made up 0.05% of Oppenheimer & Co's portfolio in Q2 2026, its #401 holding.
  • Oppenheimer & Co first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q1 2026 and has held it in 2 quarters since.
  • 31 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.